PIK3CA and neoplasm: With the promise of increased tumour efficacy of PARPi in combination with immunotherapies and other molecular targets, including the PI3K/AKT/mTOR pathway and other HR mechanisms seen in pre-clinical models, there are likely to be further biomarkers identified to aid more specific therapies.